Stock Events

Almirall SA 

€8.47
4
-€0.13-1.46% Today

Statistics

Day High
8.47
Day Low
8.47
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
1.72B
P/E Ratio
58.47
Dividend Yield
2.14%
Dividend
0.18

Upcoming

Dividends

2.14%Dividend Yield
May 23
€0.18
Jun 22
€0.19
Jun 21
€0.19
Oct 20
€0.2
Jun 19
€0.2

Earnings

19FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
0
0.08
0.15
0.23
Expected EPS
0.09
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow E2Z.F. It's not an investment recommendation.

About

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Show more...
CEO
Mr. Gianfranco Nazzi
Employees
1793
Country
ES
ISIN
ES0157097017
WKN
000A0MU8Y

Listings